HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Research Dictionary Pharma Mobile

Sign Up FREE or Login

R 306465

Subscribe to New Research on R 306465

inhibits HDAC1; structure in first source

Also Known As:

R-306465; R306465

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 58

Experts

1.	Andries, L: 1 article (11/2007)
2.	Angibaud, P: 1 article (11/2007)
3.	Janicot, M: 1 article (11/2007)
4.	Tuman, R W: 1 article (11/2007)
5.	Janssens, B: 1 article (11/2007)
6.	van Dun, J: 1 article (11/2007)
7.	Arts, J: 1 article (11/2007)
8.	Mariën, A: 1 article (11/2007)
9.	Johnson, D L: 1 article (11/2007)
10.	Floren, W: 1 article (11/2007)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 11/19/2007 - "R306465 potently inhibited cell proliferation of all main solid tumour indications, including ovarian, lung, colon, breast and prostate cancer cell lines, with IC50 values ranging from 30 to 300 nM. Haematological cell lines, including acute lymphoblastic leukaemia, acute myeloid leukaemia, chronic lymphoblastic leukaemia, chronic myeloid leukaemia, lymphoma and myeloma, were potently inhibited at a similar concentration range. "
2.	Lymphoma (Lymphomas) 11/19/2007 - "R306465 potently inhibited cell proliferation of all main solid tumour indications, including ovarian, lung, colon, breast and prostate cancer cell lines, with IC50 values ranging from 30 to 300 nM. Haematological cell lines, including acute lymphoblastic leukaemia, acute myeloid leukaemia, chronic lymphoblastic leukaemia, chronic myeloid leukaemia, lymphoma and myeloma, were potently inhibited at a similar concentration range. "
3.	Carcinoma (Carcinomatosis) 11/19/2007 - "Once-daily oral administration of R306465 at well-tolerated doses inhibited the growth of A2780 ovarian, H460 lung and HCT116 colon carcinomas in immunodeficient mice. "

Related Therapies and Procedures

1.	Oral Administration